BioMarin Pharma (BMRN) Tops Q3 EPS, Lowers FY Revenue Guidance
Get Alerts BMRN Hot Sheet
Price: $88.63 -1.6%
EPS Growth %: -45.0%
Financial Fact:
Interest income: 1.63M
Today's EPS Names:
MAXN, CSTR, ACU, More
EPS Growth %: -45.0%
Financial Fact:
Interest income: 1.63M
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 GAAP EPS of $4.01, which may not compare to the analyst estimate of $1.29. Revenue for the quarter came in at $476.8 million versus the consensus estimate of $454.64 million.
GUIDANCE:
BioMarin Pharma sees FY2020 revenue of $1.81-1.87 billion, versus prior of $1.85-$1.95 billion and the consensus of $1.86 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Schlumberger (SLB) earnings in-line, revenue beats expectations
- Parke Bancorp (PKBK) Reports Q1 EPS of $0.51
- MetroCity Bankshares, Inc. (MCBS) Tops Q1 EPS by 4c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!